LOGIN  |  REGISTER
Recursion

DocGo to Announce Fourth Quarter and Full-Year 2022 Results on Monday, March 13

February 21, 2023 | Last Trade: US$1.50 0.06 -3.85

NEW YORK / Feb 21, 2023 / Business Wire / DocGo, a leading provider of last-mile mobile health services (Nasdaq: DCGO), today announced that the company will report results for the fourth quarter and full-year ended December 31, 2022, after the markets close on Monday, March 13th. Management will host a conference call for analysts and investors at 5:00pm ET on that day.

Conference call and webcast details:

Monday, March 13th, 5:00pm ET
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13736245

To access the Call me™ feature, which avoids the need to wait for an operator, click here.

The webcast can be accessed under Events on the Investors section of the company’s website, https://ir.docgo.com/.

About DocGo

DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page